Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2008 1
2010 1
2011 4
2012 1
2013 1
2014 4
2015 1
2016 3
2017 2
2019 1
2021 1
2022 2
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

25 results

Results by year

Filters applied: . Clear all
Page 1
MET exon 14 skipping mutation is a hepatocyte growth factor (HGF)-dependent oncogenic driver in vitro and in humanised HGF knock-in mice.
Fernandes M, Hoggard B, Jamme P, Paget S, Truong MJ, Grégoire V, Vinchent A, Descarpentries C, Morabito A, Stanislovas J, Farage E, Meneboo JP, Sebda S, Bouchekioua-Bouzaghou K, Nollet M, Humez S, Perera T, Fromme P, Grumolato L, Figeac M, Copin MC, Tulasne D, Cortot AB, Kermorgant S, Kherrouche Z. Fernandes M, et al. Among authors: perera t. Mol Oncol. 2023 Nov;17(11):2257-2274. doi: 10.1002/1878-0261.13397. Epub 2023 Jul 14. Mol Oncol. 2023. PMID: 36799689 Free PMC article.
CD74-NRG1 fusions in lung adenocarcinoma.
Fernandez-Cuesta L, Plenker D, Osada H, Sun R, Menon R, Leenders F, Ortiz-Cuaran S, Peifer M, Bos M, Daßler J, Malchers F, Schöttle J, Vogel W, Dahmen I, Koker M, Ullrich RT, Wright GM, Russell PA, Wainer Z, Solomon B, Brambilla E, Nagy-Mignotte H, Moro-Sibilot D, Brambilla CG, Lantuejoul S, Altmüller J, Becker C, Nürnberg P, Heuckmann JM, Stoelben E, Petersen I, Clement JH, Sänger J, Muscarella LA, la Torre A, Fazio VM, Lahortiga I, Perera T, Ogata S, Parade M, Brehmer D, Vingron M, Heukamp LC, Buettner R, Zander T, Wolf J, Perner S, Ansén S, Haas SA, Yatabe Y, Thomas RK. Fernandez-Cuesta L, et al. Among authors: perera t. Cancer Discov. 2014 Apr;4(4):415-22. doi: 10.1158/2159-8290.CD-13-0633. Epub 2014 Jan 27. Cancer Discov. 2014. PMID: 24469108
Met inhibition revokes IFNγ-induction of PD-1 ligands in MET-amplified tumours.
Martin V, Chiriaco C, Modica C, Acquadro A, Cortese M, Galimi F, Perera T, Gammaitoni L, Aglietta M, Comoglio PM, Vigna E, Sangiolo D. Martin V, et al. Among authors: perera t. Br J Cancer. 2019 Mar;120(5):527-536. doi: 10.1038/s41416-018-0315-3. Epub 2019 Feb 6. Br J Cancer. 2019. PMID: 30723303 Free PMC article.
MET inhibition overcomes radiation resistance of glioblastoma stem-like cells.
De Bacco F, D'Ambrosio A, Casanova E, Orzan F, Neggia R, Albano R, Verginelli F, Cominelli M, Poliani PL, Luraghi P, Reato G, Pellegatta S, Finocchiaro G, Perera T, Garibaldi E, Gabriele P, Comoglio PM, Boccaccio C. De Bacco F, et al. Among authors: perera t. EMBO Mol Med. 2016 May 2;8(5):550-68. doi: 10.15252/emmm.201505890. Print 2016 May. EMBO Mol Med. 2016. PMID: 27138567 Free PMC article.
One cisplatin dose provides durable stimulation of anti-tumor immunity and alleviates anti-PD-1 resistance in an intraductal model for triple-negative breast cancer.
Steenbrugge J, Bellemans J, Vander Elst N, Demeyere K, De Vliegher J, Perera T, De Wever O, Van Den Broeck W, De Spiegelaere W, Sanders NN, Meyer E. Steenbrugge J, et al. Among authors: perera t. Oncoimmunology. 2022 Jul 22;11(1):2103277. doi: 10.1080/2162402X.2022.2103277. eCollection 2022. Oncoimmunology. 2022. PMID: 35898705 Free PMC article.
25 results